Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.

ABSTRACT: Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great heterogeneity among patients complicates therapeutic decision-making. In the past decades, development of new therapies and drugs have significantly improved survival of MM patients. However, resistance to drugs and relapse remain the most common causes of mortality and are the major challenges to overcome. The advent of high throughput omics technologies capable of analyzing big amount of clinical and biological data has changed the way to diagnose and treat MM. Integration of omics data (gene mutations, gene expression, epigenetic information, and protein and metabolite levels) with clinical hi

SUBMITTER: Ovejero S 

PROVIDER: S-EPMC9400753 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature